{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:39:10Z","timestamp":1740166750039,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41429-024-00709-3","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T10:02:37Z","timestamp":1709546557000},"page":"306-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria"],"prefix":"10.1038","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0198-8746","authenticated-orcid":false,"given":"Bel\u00e9n R.","family":"Imperiale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda B.","family":"Mancino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto D.","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"de la Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora S.","family":"Morcillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"709_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022;399:629\u201355.","journal-title":"Lancet"},{"key":"709_CR2","unstructured":"WHO. WHO Global Tuberculosis Report. 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240013131."},{"key":"709_CR3","first-page":"301","volume":"55","author":"CDC.","year":"2006","unstructured":"CDC. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide. MMWR Morb Mortal Wkly Rep. 2006;55:301\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"709_CR4","first-page":"430","volume":"81","author":"WHO.","year":"2006","unstructured":"WHO. WHO Extensively drug-resistant tuberculosis (XDR.TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006;81:430\u20132.","journal-title":"Wkly Epidemiol Rec"},{"key":"709_CR5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1164\/rccm.v201erratum2","volume":"201","author":"P Nahid","year":"2020","unstructured":"Nahid P, et al. Treatment of drug-resistant tuberculosis. an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2020;201:500\u20131.","journal-title":"Am J Respir Crit Care Med"},{"key":"709_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ja.2014.61","volume":"67","author":"BR Imperiale","year":"2014","unstructured":"Imperiale BR, Di Giulio AB, Cataldi AA, Morcillo NS. Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs. J Antibiot. 2014;67:749\u201354.","journal-title":"J Antibiot"},{"key":"709_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/AAC.48.2.596-601.2004","volume":"48","author":"AF Cheng","year":"2004","unstructured":"Cheng AF, et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2004;48:596\u2013601.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/jac\/dkg222","volume":"51","author":"J Ruiz","year":"2003","unstructured":"Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 2003;51:1109\u201317.","journal-title":"J Antimicrob Chemother"},{"key":"709_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1056\/NEJM199102073240606","volume":"324","author":"DC Hooper","year":"1991","unstructured":"Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N. Engl J Med. 1991;324:384\u201394.","journal-title":"N. Engl J Med"},{"key":"709_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0272-5231(02)00014-X","volume":"23","author":"JO Falkinham 3rd","year":"2002","unstructured":"Falkinham JO 3rd. Nontuberculous mycobacteria in the environment. Clin Chest Med. 2002;23:529\u201351.","journal-title":"Clin Chest Med"},{"key":"709_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3201\/eid170310060","volume":"17","author":"S Simons","year":"2011","unstructured":"Simons S, et al. Nontuberculous mycobacteria in respiratory tract infections. Eastern Asia. Emerg Infect Dis. 2011;17:343\u20139.","journal-title":"Emerg Infect Dis"},{"key":"709_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","volume":"36","author":"DR Prevots","year":"2015","unstructured":"Prevots DR, Marras TK. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: a review. Clin Chest Med. 2015;36:13\u201334.","journal-title":"Clin Chest Med"},{"key":"709_CR13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3201\/eid2310.170845","volume":"23","author":"E Henkle","year":"2017","unstructured":"Henkle E, Hedberg K, Schafer SD, Winthrop KL. Surveillance of extrapulmonary nontuberculous mycobacteria infections, Oregon, USA, 2007\u20132012. Emerg Infect Dis. 2017;23:1627\u201330.","journal-title":"Emerg Infect Dis"},{"key":"709_CR14","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3201\/eid2311.170959","volume":"23","author":"SK Brode","year":"2017","unstructured":"Brode SK, Marchaund-Austin A, Jamieson FB, Marras TK. Pulmonary versus nonpulmonary nontuberculous Mycobacteria, Ontario, Canada. Emerg Infect Dis. 2017;23:1898\u2013901.","journal-title":"Emerg Infect Dis"},{"key":"709_CR15","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1086\/648443","volume":"49","author":"PM Cassidy","year":"2009","unstructured":"Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis. 2009;49:e124\u2013e9.","journal-title":"Clin Infect Dis"},{"key":"709_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/jcm9082541","volume":"9","author":"K To","year":"2020","unstructured":"To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V. General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus. J Clin Med. 2020;9:254.","journal-title":"J Clin Med"},{"key":"709_CR17","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1183\/09031936.00149212","volume":"42","author":"W Hoefsloot","year":"2013","unstructured":"Hoefsloot W, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42:1604\u201313.","journal-title":"Eur Respir J"},{"key":"709_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1473-3099(04)01130-2","volume":"9","author":"PC Karakousis","year":"2004","unstructured":"Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis. 2004;9:557\u2013965.","journal-title":"Lancet Infect Dis"},{"key":"709_CR19","first-page":"3","volume":"44","author":"B Imperiale","year":"2012","unstructured":"Imperiale B, et al. Disease caused by non-tuberculous mycobacteria: diagnostic procedures and treatment evaluation in the North of Buenos Aires Province. Rev Argent Microbiol. 2012;44:3\u20139.","journal-title":"Rev Argent Microbiol"},{"key":"709_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1128\/CMR.9.2.177","volume":"9","author":"JO Falkingham","year":"1996","unstructured":"Falkingham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev. 1996;9:177\u2013215.","journal-title":"Clin Microbiol Rev"},{"key":"709_CR21","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1017\/S0950268817000139","volume":"145","author":"BR Imperiale","year":"2017","unstructured":"Imperiale BR, et al. Genetic diversity of Mycobacterium avium complex strains isolated in Argentina by MIRU-VNTR. Epidemiol Infect. 2017;145:1382\u201391.","journal-title":"Epidemiol Infect"},{"key":"709_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1471-4914(01)01983-9","volume":"7","author":"FA El-Zaatari","year":"2001","unstructured":"El-Zaatari FA, Osato MS, Graham DY. Etiology of Crohn\u2019s disease: the role of Mycobacterium avium paratuberculosis. Trends Mol Med. 2001;7:247\u201352.","journal-title":"Trends Mol Med"},{"key":"709_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1099\/00207713-40-3-254","volume":"40","author":"MF Thorel","year":"1990","unstructured":"Thorel MF, Krichevsky M, L\u00e9vy-Fr\u00e9bault VV. Numerical taxonomy of mycobactin-dependent mycobacteria, emended description of Mycobacterium avium, and description of Mycobacterium avium subsp avium subsp nov, Mycobacterium avium subsp paratuberculosis subsp nov, and Mycobacterium avium subsp silvaticum subsp nov. Int J Syst Bacteriol. 1990;40:254\u201360.","journal-title":"Int J Syst Bacteriol"},{"key":"709_CR24","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1128\/JCM.01621-07","volume":"46","author":"J Alvarez","year":"2008","unstructured":"Alvarez J, et al. Genetic diversity of Mycobacterium avium isolates recovered from clinical samples and from the environment: molecular characterization for diagnostic purposes. J Clin Microbiol. 2008;46:1246\u201351.","journal-title":"J Clin Microbiol"},{"key":"709_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/ijmy.ijmy_40_19","volume":"8","author":"A Martin","year":"2019","unstructured":"Martin A, Colmant A, Verroken A, Rodriguez-Villalobos H. Laboratory diagnosis of nontuberculous mycobacteria in a Belgium Hospital. Int J Mycobacteriol. 2019;8:157\u201361.","journal-title":"Int J Mycobacteriol"},{"key":"709_CR26","doi-asserted-by":"publisher","first-page":"1700374","DOI":"10.1183\/13993003.00374-2017","volume":"49","author":"DR Prevots","year":"2017","unstructured":"Prevots DR, Loddenkemper R, Sotgiu G, Migliori GB. Non tuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs. Eur Respir J. 2017;49:1700374.","journal-title":"Eur Respir J"},{"key":"709_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1473-3099(08)70100-2","volume":"8","author":"C Piersimoni","year":"2008","unstructured":"Piersimoni C, Scarparo C. Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis. 2008;8:323\u201334.","journal-title":"Lancet Infect Dis"},{"key":"709_CR28","first-page":"206","volume":"4","author":"JM Garc\u00eda Garc\u00eda","year":"2005","unstructured":"Garc\u00eda Garc\u00eda JM, Guti\u00e9rrez Palacios JJ, S\u00e1nchez Antu\u00f1a AA. Respiratory infections caused by environmental mycobacteria. Arch Bronconeumol. 2005;4:206\u201319.","journal-title":"Arch Bronconeumol"},{"key":"709_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1128\/AAC.00853-07","volume":"52","author":"K Hoshino","year":"2008","unstructured":"Hoshino K, et al. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother. 2008;52:65\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR30","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1128\/AAC.01545-09","volume":"54","author":"A Disratthakit","year":"2010","unstructured":"Disratthakit A, Doi N. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrob Agents Chemother. 2010;54:2684\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR31","doi-asserted-by":"publisher","first-page":"e0005013","DOI":"10.1371\/journal.pntd.0005013","volume":"10","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Yokoyama K, Nakajima C, Suzuki Y. DC-159a shows inhibitory activity against DNA gyrases of Mycobacterium leprae. PLoS Negl Trop Dis. 2016;10:e0005013. 28","journal-title":"PLoS Negl Trop Dis"},{"key":"709_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/mdr.2018.0078","volume":"25","author":"K Koide","year":"2019","unstructured":"Koide K, et al. Antibacterial activity of DC-159a against Salmonella Typhimurium. Micro Drug Resist. 2019;25:14\u201322.","journal-title":"Micro Drug Resist"},{"key":"709_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/jac\/dkm200","volume":"60","author":"M Cynamon","year":"2007","unstructured":"Cynamon M, Sklaney MR, Shoene C. Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J Antimicrob Chemother. 2007;60:429\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"709_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","volume":"169","author":"EL Nuermberger","year":"2003","unstructured":"Nuermberger EL, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2003;169:421\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"709_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1473-3099(08)70077-X","volume":"8","author":"K Drlica","year":"2008","unstructured":"Drlica K, Zhao X, Kreiswirth B. Minimising moxifloxacin resistance with tuberculosis. Lancet Infect Dis. 2008;8:273\u20135.","journal-title":"Lancet Infect Dis"},{"key":"709_CR36","first-page":"901","volume":"9","author":"A Martin","year":"2005","unstructured":"Martin A, et al. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2005;9:901\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"709_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1183\/09031936.03.00098803","volume":"23","author":"R Bals","year":"2004","unstructured":"Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004;23:327\u201333.","journal-title":"Eur Respir J"},{"key":"709_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1513\/pats.200808-088RM","volume":"6","author":"RP Schleimer","year":"2009","unstructured":"Schleimer RP, et al. Epithelium, inflammation, and immunity in the upper airways of humans: studies in chronic rhinosinusitis. Proc Am Thorac Soc. 2009;6:288\u201394.","journal-title":"Proc Am Thorac Soc"},{"key":"709_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00001432-200306000-00002","volume":"16","author":"RM Strieter","year":"2003","unstructured":"Strieter RM, Belperio JA, Keane MP. Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis. 2003;16:193\u20138.","journal-title":"Curr Opin Infect Dis"},{"key":"709_CR40","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1128\/jcm.35.4.907-914.1997","volume":"35","author":"J Kamerbeek","year":"1997","unstructured":"Kamerbeek J, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907\u201314.","journal-title":"J Clin Microbiol"},{"key":"709_CR41","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.5588\/ijtld.12.0949","volume":"17","author":"BR Imperiale","year":"2013","unstructured":"Imperiale BR, Zum\u00e1rraga MJ, Di Giulio AB, Cataldi AA, Morcillo NS. Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2013;17:1088\u201393.","journal-title":"Int J Tuberc Lung Dis"},{"key":"709_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/ijmy.ijmy_229_20","volume":"10","author":"RD Moyano","year":"2021","unstructured":"Moyano RD, et al. Genetic diversity of Mycobacterium avium sp. paratuberculosis by mycobacterial interspersed repetitive Unit-Variable number tandem repeat and multi-locus short-sequence repeat. Int J Mycobacteriol. 2021;10:51\u20139.","journal-title":"Int J Mycobacteriol"},{"key":"709_CR43","first-page":"253","volume":"8","author":"NS Morcillo","year":"2004","unstructured":"Morcillo NS, et al. A microplate indicator-based method for determining the susceptibility of multidrug-resistant M. tuberculosis to antimicrobial agents. Int J Tuberc Lung Dis. 2004;8:253\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"709_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","volume":"48","author":"JM Andrews","year":"2001","unstructured":"Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 2001;48:5\u201316.","journal-title":"J Antimicrob Chemother"},{"key":"709_CR45","first-page":"1169","volume":"14","author":"N Morcillo","year":"2010","unstructured":"Morcillo N, Imperiale B, Di Giulio B. Evaluation of MGIT 960\u2122 and the colorimetric-based method for tuberculosis drug susceptibility testing. Int J Tuberc Lung Dis. 2010;14:1169\u201375.","journal-title":"Int J Tuberc Lung Dis"},{"key":"709_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/AAC.37.1.111","volume":"37","author":"N Mor","year":"1993","unstructured":"Mor N, Heifets L. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother. 1993;37:111\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55\u201363.","journal-title":"J Immunol Methods"},{"key":"709_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","volume":"42","author":"HY Kim","year":"2017","unstructured":"Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher\u2019s exact test. Restor Dent Endod. 2017;42:152\u20135.","journal-title":"Restor Dent Endod"},{"key":"709_CR49","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1128\/AAC.00417-10","volume":"55","author":"J Sekiguchi","year":"2011","unstructured":"Sekiguchi J, Disratthakit A, Maeda S, Doi N. Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone. Antimicrob Agents Chemother. 2011;55:3958\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR50","first-page":"228","volume":"36","author":"P Pitaksajjakul","year":"2005","unstructured":"Pitaksajjakul P, et al. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health. 2005;36:228\u201337.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"709_CR51","unstructured":"Nakamura H, Horita Y. Comparative Evaluation of New Respiratory Quinolone DC-159a or Moxifloxacin Containing Regimens in a Murine TB Model. [Abstract 038] ASM Microbiome. 2017: session 035. REF: https:\/\/www.newtbdrugs.org\/pipeline\/compound\/dc-159a."},{"key":"709_CR52","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1128\/AAC.46.2.288-293.2002","volume":"46","author":"D Paillard","year":"2002","unstructured":"Paillard D, Grellet J, Dubois V, Saux MC, Quentin C. Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model. Antimicrob Agents Chemother. 2002;46:288\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR53","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1128\/AAC.01514-10","volume":"55","author":"Z Ahmad","year":"2011","unstructured":"Ahmad Z, et al. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother. 2011;55:1781\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"709_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2174\/1389557516666160606204639","volume":"17","author":"R Tandon","year":"2017","unstructured":"Tandon R, Nath M. Tackling drug-resistant tuberculosis: current trends and approaches. Mini Rev Med Chem. 2017;17:549\u201370. 2017","journal-title":"Mini Rev Med Chem"},{"key":"709_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/jmm.0.000198","volume":"65","author":"I Soni","year":"2016","unstructured":"Soni I, De Groote M, Dasgupta A, Chopra S. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. J Med Microbiol. 2016;65:1\u20138.","journal-title":"J Med Microbiol"},{"key":"709_CR56","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4155\/fmc.15.128","volume":"7","author":"D Kumar","year":"2015","unstructured":"Kumar D, Negi B, Rawat DS. The anti-tuberculosis agents under development and the challenges ahead. Future Med Chem. 2015;7:1981\u20132003.","journal-title":"Future Med Chem"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00709-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00709-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00709-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T23:03:06Z","timestamp":1714431786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-024-00709-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1038\/s41429-024-00709-3","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"type":"print","value":"0021-8820"},{"type":"electronic","value":"1881-1469"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}